Insider Trading April 1, 2026

Keysight Director Disposes $239,929 in Stock Amid Company Product and Testing Announcements

Richard P. Hamada sold 870 shares on March 30, 2026, as Keysight pushes SBOM tooling, 1.6T Ethernet test capability and automotive and terahertz initiatives

By Maya Rios KEYS
Keysight Director Disposes $239,929 in Stock Amid Company Product and Testing Announcements
KEYS

Richard P. Hamada, a director at Keysight Technologies, sold 870 shares of company stock on March 30, 2026, in a transaction totaling $239,929. The sale, reported on a Form 4 filing with the Securities and Exchange Commission, occurred as Keysight rolled out several product and testing updates spanning cybersecurity compliance tooling, high-speed Ethernet interconnect testing, automotive Ethernet validation and terahertz research collaborations. Market commentary notes the stock has climbed 88% over the past year but declined about 4% in the past week and appears overvalued against its Fair Value in InvestingPro analysis.

Key Points

  • Director Richard P. Hamada sold 870 shares on March 30, 2026, for $239,929 and now holds 42,160.266 shares directly.
  • Keysight launched the SBOM Manager for Software Bill of Materials compliance and expanded 1.6T Ethernet testing to support AI and high-performance computing networks; automotive and terahertz initiatives were also announced.
  • Stock performance shows an 88% gain over the past year, a roughly 4% decline in the last week, and InvestingPro analysis rates the stock as appearing overvalued relative to Fair Value.

Insider transaction details

According to a Form 4 filed with the Securities and Exchange Commission, Richard P. Hamada, who serves on the board of Keysight Technologies, Inc. (NYSE: KEYS), sold 870 shares of common stock on March 30, 2026. The sale was executed at an average weighted price of $275.781 per share, with execution prices spanning from $275.500 to $276.020. The total value of the disposal was $239,929. After the transaction, the filing shows Hamada directly owns 42,160.266 shares of Keysight Technologies.

Market context

Keysight shares have appreciated approximately 88% over the trailing year, though the stock has retreated roughly 4% over the last week. An InvestingPro analysis included in company commentary indicates the stock currently appears overvalued relative to its Fair Value, and notes that 16 additional InvestingPro Tips are available for those seeking deeper valuation and performance metrics.

Product and testing developments

Separately from the insider filing, Keysight announced a suite of product and test-capability updates. The company introduced the Keysight SBOM Manager, a software solution intended to help organizations generate and manage Software Bill of Materials to assist with cybersecurity compliance. The SBOM Manager is described as aligning with regulatory frameworks including the European Union Cyber Resilience Act and U.S. Executive Order 14028.

Keysight also expanded its 1.6T Ethernet interconnect testing capabilities by enhancing the INPT-1600GE and AresONE 1600GE test platforms. These enhancements are stated to support AI and high-performance computing network environments by qualifying various 1.6T-capable components.

At the Automotive Ethernet Congress in Germany, Keysight demonstrated new automotive Ethernet receiver compliance test solutions aimed at validation work for automakers and suppliers. In addition, the company reported a collaboration with AttoTude Inc. under which Keysight’s 89600 Vector Signal Analysis software is being used to develop terahertz radio technology for AI data centers.

Corporate governance

Keysight’s shareholders recently approved all proposals at the company’s annual meeting, including the election of new board members to serve three-year terms.


Key points

  • Director Richard P. Hamada sold 870 shares on March 30, 2026, for $239,929, leaving him with 42,160.266 shares directly held - impacts investor ownership snapshot and governance transparency.
  • Keysight announced multiple product and testing updates: SBOM Manager for cybersecurity compliance, expanded 1.6T Ethernet test capabilities for AI and HPC networks, automotive Ethernet receiver compliance testing, and terahertz R&D collaboration - affecting technology, cybersecurity and data center sectors.
  • Market indicators note an 88% year-over-year stock rise, a near-term decline of about 4%, and an InvestingPro view that the shares appear overvalued relative to Fair Value - relevant to equity investors and market analysts.

Risks and uncertainties

  • The InvestingPro assessment that Keysight appears overvalued relative to its Fair Value poses valuation risk for equity investors in the technology sector.
  • Recent short-term stock weakness of about 4% over the past week introduces near-term market volatility risk for shareholders and potential buyers.
  • Information on product impacts is descriptive rather than quantitative in the filing; the actual commercial or technical impact of the announced tools and test enhancements on revenue or adoption is not detailed in the available material.

Contact and additional information

The SEC Form 4 filing is the record for the insider transaction. Additional investing analysis referenced is available through InvestingPro tips as noted in company disclosures.

Risks

  • InvestingPro analysis indicates the stock appears overvalued relative to its Fair Value, posing valuation risk for technology equity investors.
  • A recent approximately 4% decline over the last week highlights short-term market volatility risk for shareholders.
  • The company’s product and testing announcements are described without quantitative commercial impact, leaving uncertainty about near-term revenue or adoption implications for the technology and data center sectors.

More from Insider Trading

Curis Director Acquires $5,487 Stake as Shares Hover Near 52-Week Low Apr 1, 2026 US Energy CEO Buys 15,000 Shares as Company Advances Helium and CO2 Processing Project Apr 1, 2026 Alphabet Executive Disposes $2.48M in Class C Shares Amid Ongoing AI Product Updates Mar 31, 2026 Fairmount Funds Sells Cogent Biosciences Stake After Preferred Conversion; FDA Clears Key Filing for Bezuclastinib Mar 31, 2026 Ramaco Director Disposes $3.05M in Shares Amid Volatile Trading Mar 31, 2026